Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models

Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models

This study evaluated suvecaltamide, a selective T-type calcium channel modulator, on chemotherapy-induced peripheral neurotoxicity (CIPN) and anti-cancer activity associated with bortezomib (BTZ). Rats received BTZ (0.2 mg/kg thrice weekly) for 4 weeks, then BTZ alone (<i>n</i> = 8) or B...

Full description

Bibliographic Details
Main Authors: Cristina Meregalli, Yuri Maricich, Guido Cavaletti, Annalisa Canta, Valentina A. Carozzi, Alessia Chiorazzi, Evan Newbold, Paola Marmiroli, Cecilia Ceresa, Arthur Diani, Spyros Papapetropoulos, Margaret S. Lee
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
suvecaltamide
CX-8998
JZP385
non-interference
reversal
bortezomib
Online Access:https://www.mdpi.com/2072-6694/13/19/5013

Internet

https://www.mdpi.com/2072-6694/13/19/5013

Similar Items